STXS Strangle Strategy
STXS (Stereotaxis, Inc.), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on AMEX.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents.
STXS (Stereotaxis, Inc.) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $180.3M, a beta of 1.33 versus the broader market, a 52-week range of 1.74-3.59, average daily share volume of 415K, a public-listing history dating back to 2004, approximately 139 full-time employees. These structural characteristics shape how STXS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.33 indicates STXS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on STXS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current STXS snapshot
As of May 15, 2026, spot at $1.88, ATM IV 358.80%, IV rank 100.00%, expected move 102.87%. The strangle on STXS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on STXS specifically: STXS IV at 358.80% is rich versus its 1-year range, which makes a premium-buying STXS strangle relatively expensive in absolute-cost terms, with a market-implied 1-standard-deviation move of approximately 102.87% (roughly $1.93 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated STXS expiries trade a higher absolute premium for lower per-day decay. Position sizing on STXS should anchor to the underlying notional of $1.88 per share and to the trader's directional view on STXS stock.
STXS strangle setup
The STXS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With STXS near $1.88, the first option leg uses a $1.97 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed STXS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 STXS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.97 | N/A |
| Buy 1 | Put | $1.79 | N/A |
STXS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
STXS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on STXS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on STXS
Strangles on STXS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the STXS chain.
STXS thesis for this strangle
The market-implied 1-standard-deviation range for STXS extends from approximately $-0.05 on the downside to $3.81 on the upside. A STXS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current STXS IV rank near 100.00% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on STXS at 358.80%. As a Healthcare name, STXS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to STXS-specific events.
STXS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. STXS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move STXS alongside the broader basket even when STXS-specific fundamentals are unchanged. Always rebuild the position from current STXS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on STXS?
- A strangle on STXS is the strangle strategy applied to STXS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With STXS stock trading near $1.88, the strikes shown on this page are snapped to the nearest listed STXS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are STXS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the STXS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 358.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a STXS strangle?
- The breakeven for the STXS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current STXS market-implied 1-standard-deviation expected move is approximately 102.87%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on STXS?
- Strangles on STXS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the STXS chain.
- How does current STXS implied volatility affect this strangle?
- STXS ATM IV is at 358.80% with IV rank near 100.00%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.